Q1 2023 Telix Pharmaceuticals Ltd Activities Report Call Transcript
Good morning. Thanks, Ashley, and thank you, everybody, for joining our investor call today to discuss the Appendix 4C and cash flow statement activities report, which we lodged with the ASX aftermarket -- after the market closed yesterday.
As mentioned, I'm Kyahn Williamson, SVP of Investor Relations and Corporate Communications, and I'm joined today by Dr. Christian Behrenbruch, our Group CEO and Managing Director; Darren Smith, our Group CFO; and Colin Hayward, our Group Chief Medical Officer.
Today, we'll be taking you through the presentation that was lodged on the ASX and it's also displayed on the webcast for those joining by the phone. So those by phone, we'll give a verbal cue for each slide change, and then we'll go to Q&A at the end of the call.
So just advance being through the disclaimer and to Slide 3. So Slide 3, by way of summary, the milestones and achievements of Q1 2023 really demonstrate how we are delivering against our growth strategy and delivering in our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |